Quick Links
Past Events

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Incyte, and Merck Sharp & Dohme Corp.

Privacy Policy
Terms & Conditions
Executive Board
Faculty Portal
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

Immuno-Oncology Strategies to Treat Bladder Cancer

Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology Strategies

Saturday, May 19, 2018
Dinner and Registration: 5:30 PM – 6:00 PM
Scientific Session: 6:00 PM – 8:00 PM

Moscone Convention Center (MCC SOUTH, Level Two, 216)
747 Howard Street
San Francisco, CA


Clinical decision making in the setting of bladder cancer has dramatically changed in recent years, with the approvals of several immune checkpoint inhibitors that have improved patient outcomes. How will this impact your urology practice? How will you incorporate immunotherapy into treatment planning? How will you counsel your patients regarding these new agents and their unique safety profiles? Use of checkpoint inhibitors across multiple lines of therapy for advanced bladder cancer and the potential expansion of their use to early-stage disease makes it imperative that you, as a member of the multidisciplinary care team, understand both new data and best practices related to the use of immunotherapies.

We invite you to attend Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology Strategies, a live continuing medical education symposium to be held adjunct to the American Urological Association annual meeting in San Francisco. This program will grant you an opportunity to learn from, and interact with, an expert panel of physicians in a dynamic setting. Please join us for a review of practice-changing data and how they impact patient care. Brief didactic presentations, followed by real-world interactive clinical case discussions, will help you interpret and apply the evidence. To set your focus on key emerging data, the faculty will share their forward-looking perspectives on the horizon of bladder cancer treatment, based on recently reported and anticipated clinical trial data.

This exciting educational event will augment your foundation of knowledge and clinical competence in several areas, including:

  • Why immunotherapy is effective in bladder cancer
  • The clinical significance for urologists of pivotal and emerging data from clinical studies of immunotherapy-based approaches across all stages of bladder cancer
  • Consideration of immunotherapy in contemporary urology clinical decision making and patient counseling

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca, Incyte, and Merck Sharp & Dohme Corp.

Target Audience

This educational program is directed toward urologists, oncologists, and researchers interested in the treatment of bladder cancers. Nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with bladder cancers are also invited to participate.

Learning Objectives:

Upon completion of this activity, participants will be able to:

  • Explain the mechanistic rationale that underlies the investigation and clinical development of immunotherapeutic approaches to manage bladder cancer
  • Evaluate pivotal trial findings from studies that have evaluated immunotherapies for the management of patients with bladder cancer and emerging information concerning the role of biomarkers, combination strategies, and adjuvant approaches in this regard
  • Place practice-changing evidence concerning the use of immuno-oncology strategies to treat bladder cancer in the context of managing these patients in contemporary urological cancer care settings

Program Chair

Daniel P. Petrylak, MD
Professor of Medicine (Medical Oncology) and Urology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale Cancer Center
New Haven, CT

Become a Member

Forgot Password?
Calendar of Events
Filter By